Carcinoma in situ of skin of left upper limb, including shoulder
ICD-10 D04.62 is a billable code used to indicate a diagnosis of carcinoma in situ of skin of left upper limb, including shoulder.
Carcinoma in situ (CIS) of the skin represents a localized, non-invasive form of skin cancer where abnormal cells are present but have not invaded deeper tissues. In the case of D04.62, this condition specifically affects the skin of the left upper limb, including the shoulder. CIS is often detected through skin examinations and biopsies, and it is characterized by the presence of atypical keratinocytes confined to the epidermis. Risk factors for developing CIS include prolonged sun exposure, fair skin, and a history of skin cancer. Surveillance protocols typically involve regular dermatological evaluations to monitor for changes in the lesion's appearance or behavior. Although CIS is not life-threatening, there is a risk of progression to invasive carcinoma if left untreated, necessitating timely intervention. Treatment options may include surgical excision, cryotherapy, or topical chemotherapy, depending on the lesion's characteristics and patient factors.
Detailed descriptions of the lesion, biopsy results, and treatment plans.
Patients presenting with suspicious skin lesions requiring biopsy and follow-up.
Ensure accurate documentation of lesion characteristics and patient history to support coding.
Comprehensive treatment plans and follow-up care documentation.
Management of patients with a history of skin cancer or those undergoing surveillance for CIS.
Documenting the risk of progression to invasive carcinoma is crucial for accurate coding.
Used when a biopsy is performed to confirm CIS.
Document the site, size, and method of biopsy.
Dermatologists should ensure clear documentation of the lesion's characteristics.
Carcinoma in situ is a critical diagnosis as it indicates the presence of abnormal cells that have not invaded surrounding tissues. Early detection and treatment are essential to prevent progression to invasive cancer.
